Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-12
    E.g., 2018-11-12

Articles

19446 items
12:00 AM, Nov 15, 1993  |  BioCentury | Strategy

BIOX to expand Synvisc marketing

BIOX to expand Synvisc marketing Biomatrix Inc., after accepting some compromises to push its Synvisc osteoarthritis treatment into Canada in 1992, now has its sights on a series of major market milestones through the first part...
12:00 AM, Nov 15, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

MedImmune Inc. (MEDI) Maykin Ho of Goldman Sachs started coverage with a "buy" and a target price for the end of 1994 of $38. She said the company is targeting infectious diseases with a high...
12:00 AM, Nov 15, 1993  |  BioCentury | Strategy

Pursestrings and shoestrings

All chief financial officers worth their salt know that they need to invoke the standard methods of controlling costs, linking operating milestones with financial planning, and that the best way to keep spending down is...
12:00 AM, Nov 08, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Repligen Corp. Mark Simon of Robertson, Stephens initiated coverage of Repligen Corp. with a "buy" up to $12. The stock is just $1.50 above its low, with a market cap of $83 million, because RGEN is...
12:00 AM, Nov 08, 1993  |  BioCentury | Strategy

CHIR plan: Raise money and buy technology

CHIR plan: Raise money and buy technology Chiron Corp. has decided that beneficial interest rates offer an opportunity for the company to embark on a technology acquisition campaign and to expand the company's manufacturing base. The...
12:00 AM, Nov 08, 1993  |  BioCentury | Regulation

FDA gives a thumbs up to bST

WASHINGTON - The FDA on Friday approved Monsanto Co.'s recombinant bovine somatotropin (bST) for increasing milk production in dairy cows with no restrictions other than a program of post-approval monitoring. Monsanto will have to wait...
12:00 AM, Nov 08, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Centocor Inc. (CNTO) Joseph Edelman of Prudential Securities raised his rating to "buy" from "hold," saying he has increased confidence that CNTO is poised for a turnaround. He said the company's lead monoclonal antibody,...
12:00 AM, Nov 08, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Protein Design Labs Inc. (PDLI) Stuart Weisbrod of Merrill Lynch raised his intermediate-term rating to "buy" from "above average" after the company announced its strategic alliance with Corange Ltd. He said the agreement was a...
12:00 AM, Nov 08, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Immunex Corp. (IMNX) Peter Drake of Vector Securities International lowered his rating to "sell" from "neutral." He has a 12-month price target of $9-$10. Drake said the new IMNX faces a difficult year of transition...
12:00 AM, Nov 08, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

CytoTherapeutics Inc. (CTII) Mabon Securities analyst Marc Ostro began coverage with a "buy," citing impressive efficacy data for CTII's implantable CRIB device in alleviating disease symptoms in rodent and primate models of Parkinson's, intractable...

Pages